Search results for #SGLT2i
Excellent meta-analysis @ESC_Journals #ejhf showing #SGLT2i reversing the cardiac remodelling in 555 patients with #HFrEF @BSHeartFailure @TheresaMcDonag3 @MarcoMetra @JavedButler1 #CardioTwitter doi.org/10.1002/ejhf.3…
Effect of #Luseogliflozin and Dipeptidyl-Peptidase 4 Inhibitors on the Quality-of-Life and Treatment Satisfaction of Patients With #Type2Diabetes Read the sub-analysis of the J-SELECT study here: link.springer.com/article/10.100… #diabetes #t2d #SGLT2i #DPP4i
@JACCJournals @Zordoky_Lab @MohamedDabour91 @MinaYGeorge13 @maryraphel22 @BlaesAnneMD A lot of hype around #SGLT2i. Be bareful 💰💰
🚨 Fighting diabetes, kidney disease and heart disease. Hey doctor: R YOU the problem? 🚨🚨 “it seems likely that the larger barrier is doctors’ inertia in updating their practice patterns.” 👉🏼 THREE options to help your patients and make a huge difference. #Flozins #SGLT2i
#BalanceDHF Milestone❗️ First pts enrolled in #BalanceDHF RCT studying unique #MRmodulator balcinrenone in combo w #SGLT2i dapagliflozin Seeking to expand therapeutic options in HF+CKD across the full spectrum of LVEF! Long way to go, but 💪🏾 global team classic.clinicaltrials.gov/ct2/show/NCT06…
Do #SGLT2i have a role in #CardioOnc? This review article highlights the cardioprotective evidence and the anticancer potential of SGLT2i in cardio-oncology. bit.ly/4ccqRCd #JACCCardioOnc @Zordoky_Lab @MohamedDabour91 @MinaYGeorge13 @maryraphel22 @BlaesAnneMD
Effects of #GDMT across Kidney Function Spectrum ✅ #BB: consistent benefit to eGFR 30 ✅ #ARNI: consistent benefit to eGFR 30 ✅ #SGLT2i: consistent benefit to eGFR 20 ❌ #SteroidalMRA: ↓ benefit & worse safety at lower eGFR New strategies to block MR axis in HF & CKD needed!
🔴 Contemporary Use & Implications of Beta-Blockers in Ptsw/ HFmrEF or HFpEF: The DELIVER Trial ✅BB use wasn't linked to #worseningHF or #cvDeath. Benefits of #dapa remained regardless of BBs, reassuring their role in Rx HFpEF/ HFmrEF alongside #SGLT2i. bit.ly/4b2jQCQ
Quadruple therapy w/ #ARNI, BB, MRA, #SGLT2i led to decreased risk of CV death & HHF in pts w/ #HFmrEF & #HFpEF. This benefit is largely driven by ARNI, MRA, SGLT2i, which was more pronounced in HFmrEF. bit.ly/3UtIEOD #JACCHF #GDMT #CHF @Cardiaficionado @GGiannakoulas
Analysis of #DELIVER trial shows that beta-blocker use wasn't linked to #worseningHF or #cvDeath. Benefits of #dapagliflozin remained consistent regardless of beta-blockers, reassuring their role in treating #HFpEF or #HFmrEF alongside #SGLT2i. bit.ly/4b2jQCQ #JACCHF
@AKronbichler Shouldn’t get too excited! The non-significant het tests (for the primary & eGFR slope outcomes) suggest the best estimate of the effect of #SGLT2i in #CKD in different regions is the overall EMPA-KIDNEY results (also true for Japan vs non-Japan regions)
Thanks to energetic collaboration (& a streamlined protocol), 612 patients with #CKD were recruited in EMPA-KIDNEY in Japan (a country unrepresented in trials & where lifetime kidney failure risk is high). Data on #SGLT2i by region (incl. Japan) out now! link.springer.com/article/10.100…
#SGLT2i and the risk of #AF in patients with type 2 diabetes: a population-based cohort study academic.oup.com/ehjcvp/article…
SGLT2is increase risk of genital mycotic infection but not #UTI. Withdrawal of #SGLT2i led to adverse outcomes in #heartfailure. SGLT2i should be continued along with treatment for mild-moderate UTI/GMI. bit.ly/3U4K3cX (2/2) #JACC @vkittipibul @robmentz
Fabulous @diabmedwiley symposium on #Kidneydisease in #diabetes at #DUKPC24 chaired by @Chillslincoln79 & Janaka Karalliedde - featuring wonderful talks from a group of clinical and academic stars 🌟 #DUKPC #diabetesuk #nephropathy #SGLT2i #glycocalyx
With the growing popularity of #SGLT2i drugs, now also for people without diabetes, it's difficult to understand why doctors have difficulty in adopting #lowcarb approach to manage diabetes & weight! Isn't the drug doing what low-carb can do without any chemical?
Go team @UoLRenalGroup 👏🏻👏🏻Looking forward to presenting this work at the Early Career Investigator session this afternoon 👩🏼🔬 #womeninSTEM #phdchat #DUKPC24 #AcademicChatter #SGLT2i #KidneyDisease
Go team @UoLRenalGroup 👏🏻👏🏻Looking forward to presenting this work at the Early Career Investigator session this afternoon 👩🏼🔬 #womeninSTEM #phdchat #DUKPC24 #AcademicChatter #SGLT2i #KidneyDisease
